SHARKS impress the Street in Q4! Namita Thapar's Emcure Pharma shares hit 10%, Ghazal Alagh's Honasa Consumer zooms 20%

Emcure Pharmaceuticals

Emcure Pharmaceuticals on Thursday, May 22, reported a 63% rise in consolidated profit after tax (PAT) to ₹197 crore during the March quarter.

The Pune-headquartered firm reported a profit after tax (PAT) of ₹121 crore a year ago.

During the January-March period, Emcure Pharmaceuticals' revenue from operations stood at ₹2,116 crore, up 19.5% year-on-year from ₹1,771 crore logged in the corresponding quarter of the previous fiscal year.

The company said the quarter saw strong performance across both its domestic and international businesses.

Emcure's domestic business grew 24.8% year-on-year, led by its women's health and cardio franchises. Meanwhile, the international business registered a growth of 15.6%.

"In Europe, we recently acquired a portfolio of products and secured key regulatory approvals, which will aid growth going forward," Emcure Pharmaceuticals said.

Emcure Pharmaceuticals Ltd CEO and Managing Director Satish Mehta said, "Over the past year, we have effectively executed our strategies across both domestic and international markets. On the domestic side, we have expanded our covered market and built a strong product pipeline of upcoming launches."

Honasa Consumer

Honasa Consumer, according to news reports, reported a net profit of ₹24.9 crore for the quarter under review, down 18% from ₹30.5 crore logged in the year-ago period. It had posted a profit of ₹26 crore in the previous quarter, as per the regulatory filing.

Profit for the full financial year FY25, however, fell by a sharp 32% to ₹72.6 crore, as against ₹110.5 crore seen in the previous year.

The firm's revenue from operations rose 13% year-on-year (YoY) to ₹533.5 crore in Q4, up from ₹471 crore registered last year, and ₹517.5 crore in the previous quarter.

Honasa's gross profit margin improved to 70.7% in Q4 FY25, up 76 bps YoY, driven by an improved product mix and operational efficiencies, reports added.

Key Highlights

• In its earnings release, the company said that Mamaearth’s strategy shift showed green shoots with double-digit YoY growth in key categories across e-commerce and modern trade in Q4 FY25, backed by building leadership in focus categories, optimal media mix modelling, and awareness-led brand building;

• NielsenIQ reported Mamaearth sustained strong consumer demand with share gains across key categories, entered the top 5 in face wash market share, and expanded retail distribution by 26% YoY to 2.36 lakh outlets;

• Younger brands continued their growth momentum with 30%+ YoY growth in FY25; and

• The Derma Co. hit ₹100 crore ARR in offline channels.

Management commentary

Varun Alagh, Chairman and CEO & Co-founder, Honasa Consumer Limited, said, "FY25 has been a year of learnings, focus, and disciplined execution. Despite its ups and downs, we’ve seen green shoots emerge, with the business delivering double-digit growth and strong momentum across our key brands. In Q4 FY25, we achieved revenue of ₹534 Cr, growing 13.3% YoY—significantly ahead of the broader FMCG market."